ResMed (NYSE:RMD) CEO Sells $1,252,890.73 in Stock

Key Points

• ResMed CEO Michael Farrell sold 4,991 shares on March 9 for a total of $1,252,890.73 (avg $251.03), trimming his stake by about 1.06% to 466,223 shares worth roughly $117.0 million.
• Quarterly results beat expectations: ResMed reported $2.81 EPS vs. $2.68 expected and revenue of $1.42 billion (up 11% year‑over‑year), with strong profitability metrics including a 27.5% net margin.
• The company declared a quarterly dividend of $0.60 (annualized $2.40) with a 1.0% yield; the ex‑dividend date was February 12 and the payment date is March 19.

ResMed Inc. (NYSE:RMD - Get Free Report) CEO Michael Farrell sold 4,991 shares of the firm's stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $251.03, for a total value of $1,252,890.73. Following the completion of the transaction, the chief executive officer owned 466,223 shares of the company's stock, valued at approximately $117,035,959.69. This represents a 1.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ResMed Price Performance

RMD traded down $5.67 during trading on Wednesday, reaching $241.45. The stock had a trading volume of 219,664 shares, compared to its average volume of 1,074,794. ResMed Inc. has a one year low of $199.92 and a one year high of $293.81. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.32 and a current ratio of 3.06. The business has a 50-day moving average of $255.50 and a 200-day moving average of $259.25. The stock has a market cap of $35.17 billion, a PE ratio of 23.88, a PEG ratio of 1.68 and a beta of 0.88.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. ResMed had a return on equity of 25.20% and a net margin of 27.53%.The business had revenue of $1.42 billion during the quarter, compared to analysts' expectations of $1.40 billion. During the same quarter last year, the business posted $2.43 EPS. The business's revenue was up 11.0% on a year-over-year basis. As a group, equities research analysts anticipate that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Thursday, February 12th. ResMed's payout ratio is presently 23.74%.

Institutional Trading of ResMed

Large investors have recently made changes to their positions in the company. SJS Investment Consulting Inc. boosted its holdings in shares of ResMed by 1,433.3% in the third quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 86 shares during the period. International Assets Investment Management LLC purchased a new position in ResMed during the 4th quarter worth $25,000. ORG Partners LLC increased its stake in ResMed by 181.6% in the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider's stock valued at $26,000 after purchasing an additional 69 shares during the period. Imprint Wealth LLC purchased a new stake in shares of ResMed in the third quarter valued at about $26,000. Finally, WFA of San Diego LLC acquired a new stake in shares of ResMed during the second quarter worth about $26,000. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

RMD has been the topic of several analyst reports. UBS Group reissued a "buy" rating and set a $345.00 price objective on shares of ResMed in a research note on Friday, December 12th. Piper Sandler increased their price target on ResMed from $270.00 to $275.00 and gave the stock a "neutral" rating in a research report on Friday, January 30th. Robert W. Baird set a $281.00 target price on ResMed in a report on Friday, January 30th. Weiss Ratings upgraded shares of ResMed from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Monday, February 9th. Finally, Wells Fargo & Company raised their price target on ResMed from $265.00 to $270.00 and gave the stock an "equal weight" rating in a report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $299.27.

About ResMed

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.